Screener
Cytek Biosciences, Inc. CTKB Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 53.2%-1.2pp | 51.7%-3.2pp | 51.8%-3.6pp | 53.5%-1.5pp | 54.4%-0.5pp | |
| Operating margin | -21.6%— | -21.5%— | -20%— | —— | —— | |
| Net margin | -39%— | -36.2%— | -33%— | —— | —— | |
| Returns | ||||||
| Return on equity | -23%— | -20.9%— | -18%— | —— | —— | |
| Return on invested capital | -15.3%— | -14.4%— | -12.6%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.5×-0.7× | 4.7×-0.9× | 5×-0.8× | 5.2×-1.0× | 5.2×-2.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.49-16.4% | $2.55-13.9% | $2.68-11.7% | $2.97+2.2% | $2.97+0.5% | |
| Valuation | ||||||
| Market capitalization | $545.93M+25.6% | $561.76M+9.4% | $645.72M-22.8% | $441.47M-39.4% | $409.11M-44.0% | |
| Price / sales | 2.6×+0.4× | 2.8×+0.1× | 3.2×-1.0× | 2.2×-1.4× | 2.1×-1.6× | |
| Price / book | 1.9×+0.6× | 1.7×+0.4× | 1.9×-0.2× | 1.2×-0.7× | 1.1×-0.8× |
FAQ
- What are Cytek Biosciences, Inc.'s profit margins?
- Cytek Biosciences, Inc. (CTKB) runs a 53.2% gross margin and a -21.6% operating margin, with a -39.0% net margin.
- Where do Cytek Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
